Clinical Trial: A Study Comparing Effectiveness of Kesimpta(R) (Ofatumumab) Versus Ocrevus(R) (Ocrelizumab) in Real-world Practice

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07779460) titled 'A Study Comparing Effectiveness of Kesimpta(R) (Ofatumumab) Versus Ocrevus(R) (Ocrelizumab) in Real-world Practice' on Aug. 18.

Brief Summary: This study aims to generate real-world evidence on the clinical effectiveness and economic burden of ofatumumab (OMB) versus ocrelizumab (OCR) in patients diagnosed with multiple sclerosis (MS) in the United States (US). Clinical effectiveness will be assessed using annualized relapse rate (ARR), while economic burden will be assessed using healthcare resource utilization (HCRU) and healthcare costs (HCC). This study will use two primary data sources that capture longitudinal, de-identified h...